Glenmark receives USFDA nod for generic Trospium tablets

Drug maker Glenmark Pharmaceuticals today said it has received US health regulator's nod to sell generic trospium tablets, used for treating urinary problems, in the American market.

Glenmark Generics Inc, a US-based subsidiary of the company has got a final approval from the US Food and Drug Administration (US FDA) for marketing and distribution of trospium tablets in 20 mg strength, Glenmark Pharmaceuticals said in a filing to Bombay Stock Exchange (BSE).

Trospium tablets are indicated in the treatment of over-active bladder, a condition that causes a sudden and unstoppable urge to urinate even though the bladder may contain less amount of urine with symptoms of involuntary leakage of urine, urgency and urinary frequency.

These tablets are generic version of Sanctura tablets manufactured by Allergan Inc, a major multi-specialty health care provider.

According to IMS Health, Sanctura tablets have achieved annual sales of $25 million for twelve-month period ended June 30, 2010.

With today's approval, Glenmark's total final approval in the second quarter of this fiscal has gone up to eight along with two tentative approvals.

The company is currently authorised to distribute 61 products in the US and has 45 products pending approval with US FDA.

The company's shares were trading at Rs 269.60 on in the late afternoon trade, up 1.03 per cent from its previous close.

image
Business Standard
177 22
Business Standard

Glenmark receives USFDA nod for generic Trospium tablets

Press Trust of India  |  New Delhi 



Glanmark Pharmaceuticals

Drug maker Glenmark Pharmaceuticals today said it has received US health regulator's nod to sell generic trospium tablets, used for treating urinary problems, in the American market.

Glenmark Generics Inc, a US-based subsidiary of the company has got a final approval from the US Food and Drug Administration (US FDA) for marketing and distribution of trospium tablets in 20 mg strength, Glenmark Pharmaceuticals said in a filing to Bombay Stock Exchange (BSE).

Trospium tablets are indicated in the treatment of over-active bladder, a condition that causes a sudden and unstoppable urge to urinate even though the bladder may contain less amount of urine with symptoms of involuntary leakage of urine, urgency and urinary frequency.

These tablets are generic version of Sanctura tablets manufactured by Allergan Inc, a major multi-specialty health care provider.

According to IMS Health, Sanctura tablets have achieved annual sales of $25 million for twelve-month period ended June 30, 2010.

With today's approval, Glenmark's total final approval in the second quarter of this fiscal has gone up to eight along with two tentative approvals.

The company is currently authorised to distribute 61 products in the US and has 45 products pending approval with US FDA.

The company's shares were trading at Rs 269.60 on in the late afternoon trade, up 1.03 per cent from its previous close.

RECOMMENDED FOR YOU

Glenmark receives USFDA nod for generic Trospium tablets

Drug maker Glenmark Pharmaceuticals today said it has received US health regulator's nod to sell generic trospium tablets, used for treating urinary problems, in the American market.

Drug maker Glenmark Pharmaceuticals today said it has received US health regulator's nod to sell generic trospium tablets, used for treating urinary problems, in the American market.

Glenmark Generics Inc, a US-based subsidiary of the company has got a final approval from the US Food and Drug Administration (US FDA) for marketing and distribution of trospium tablets in 20 mg strength, Glenmark Pharmaceuticals said in a filing to Bombay Stock Exchange (BSE).

Trospium tablets are indicated in the treatment of over-active bladder, a condition that causes a sudden and unstoppable urge to urinate even though the bladder may contain less amount of urine with symptoms of involuntary leakage of urine, urgency and urinary frequency.

These tablets are generic version of Sanctura tablets manufactured by Allergan Inc, a major multi-specialty health care provider.

According to IMS Health, Sanctura tablets have achieved annual sales of $25 million for twelve-month period ended June 30, 2010.

With today's approval, Glenmark's total final approval in the second quarter of this fiscal has gone up to eight along with two tentative approvals.

The company is currently authorised to distribute 61 products in the US and has 45 products pending approval with US FDA.

The company's shares were trading at Rs 269.60 on in the late afternoon trade, up 1.03 per cent from its previous close.

image
Business Standard
177 22
Widgets Magazine

More News

  • Sachin Bansal & Binny Bansal, Flipkart Flipkart improves customer service
  • New a/c rules to hit FMCG firms’ reported revenue New a/c rules to hit FMCG firms' reported revenue
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard